论文部分内容阅读
卵巢癌是妇科三大恶性肿瘤之一,其死亡率居妇科恶性肿瘤首位,利用卵巢癌细胞表面标志分子的特异性,使化疗药物选择性地与卵巢癌细胞结合,可有效地消除肿瘤复发和抑制肿瘤耐药。寻找卵巢癌转移相关分子标记物并对其进行靶向治疗已成为研究热点,目前研究发现MyD88与CD44在卵巢癌中均有表达,并且在卵巢癌的发生发展和侵袭转移、耐药过程中起重要作用,本文着重对CD44~+/MyD88~+卵巢癌细胞的转移、化疗耐药及预后的研究进展进行综述。
Ovarian cancer is one of the three major malignant tumors in gynecology. Its mortality is the highest among gynecological malignancies. Using the specificity of ovarian cancer cell surface marker molecules, ovarian cancer selectively binds to ovarian cancer cells and effectively eliminates tumor recurrence and Inhibit tumor drug resistance. Looking for molecular markers of ovarian cancer metastasis and targeted therapy has become a research focus, the current study found that MyD88 and CD44 are expressed in ovarian cancer, and in the development of ovarian cancer and invasion and metastasis, resistance process Important role, this article focuses on the CD44 ~ + / MyD88 ~ + ovarian cancer cell metastasis, chemoresistance and prognosis of research progress are reviewed.